CAJ | 학술논문

目的：本研究旨在评价替吉奥（S-1）联合奥沙利铂（SOX方案）一线治疗晚期食管癌的临床疗效和毒副反应。方法 SOX方案一线治疗35例食管癌患者。具体用法：替吉奥胶囊60mg，早晚餐后30min口服，连服14d；奥沙利铂130mg/m2加人5%葡萄糖液500mL中静脉滴注3h，第1天；21d为一周期，每2周期按WHO疗效标准评价疗效，所有患者至少接受2周期化疗。结果35例患者共接受113个周期的化疗，所有患者均可评价疗效。35例患者中无完全缓解病例，部分缓解17例（48.57％），稳定5例（14.29％），进展13例（37.14％），总有效率为62.86％，中位疾病进展时间187d，中位生存时间287d。最常见的不良反应为胃肠道反应及血液系统毒性，Ⅲ～Ⅳ级恶心/呕吐发生率为8.57％，Ⅲ～Ⅳ级粒细胞减少、Ⅲ～Ⅳ级血小板减少、Ⅲ～Ⅳ级贫血的发生率分别为8.57％，5.71％，5.71％；黏膜炎及腹泻多数为轻度，Ⅲ级毒性均为1例，经对症治疗后均可缓解；神经系统毒性较轻微，主要为Ⅰ级，无Ⅲ级以上外周神经毒性发生；肝毒性主要表现为ALT升高，但毒性较轻微，无Ⅱ级以上肝毒性。结论替吉奥联合奥沙利铂方案一线治疗晚期食管癌疗效满意、毒性较低，值得临床应用及进一步大样本、多中心研究。
목적：본연구지재평개체길오（S-1）연합오사리박（SOX방안）일선치료만기식관암적림상료효화독부반응。방법 SOX방안일선치료35례식관암환자。구체용법：체길오효낭60mg，조만찬후30min구복，련복14d；오사리박130mg/m2가인5%포도당액500mL중정맥적주3h，제1천；21d위일주기，매2주기안WHO료효표준평개료효，소유환자지소접수2주기화료。결과35례환자공접수113개주기적화료，소유환자균가평개료효。35례환자중무완전완해병례，부분완해17례（48.57％），은정5례（14.29％），진전13례（37.14％），총유효솔위62.86％，중위질병진전시간187d，중위생존시간287d。최상견적불량반응위위장도반응급혈액계통독성，Ⅲ～Ⅳ급악심/구토발생솔위8.57％，Ⅲ～Ⅳ급립세포감소、Ⅲ～Ⅳ급혈소판감소、Ⅲ～Ⅳ급빈혈적발생솔분별위8.57％，5.71％，5.71％；점막염급복사다수위경도，Ⅲ급독성균위1례，경대증치료후균가완해；신경계통독성교경미，주요위Ⅰ급，무Ⅲ급이상외주신경독성발생；간독성주요표현위ALT승고，단독성교경미，무Ⅱ급이상간독성。결론체길오연합오사리박방안일선치료만기식관암료효만의、독성교저，치득림상응용급진일보대양본、다중심연구。
Objective This study was to evaluate the efficacy and toxicity of SOX regimen as first-line chemotherapy for advanced esophageal carcinoma (AEC) patients.Methods Thirty-five patients with pathologically confirmed AEC were entered into the study. They received S-1 (60mg, bid, days 1 to 14) and oxaliplatin (130mg/m2, day 1) every 3 weeks. Treatment efficacy was evaluated every six weeks based on the WHO standard. All patients received at least two cycles of therapy.Results Patients received a total of 113 cycles of treatment, and all were evaluable for efficacy and toxicity. The overall response rate was 62.86%. No complete response (CR) was achieved, 17 (48.57%) achieved partial responses (PRs), 5 (14.29%) had stable disease (SD), and 13 had progression disease (PD). The median time to progression (TTP) was 187 days and the median survival time (MST) was 287 days. Hematologic toxicity included 3 cases (8.57%) of grade Ⅲ~Ⅳ neutropenia, and two cases of grade Ⅲ~Ⅳ thrombocytopenia. The main non-hematologic toxicity included three cases of grade Ⅲ nausea/vomiting (8.57%).ConclusionSOX regimen is effective and well tolerated as first-line chemotherapy for AEC patients.